Research
Hormonal
Bariatric surgery prevents the onset of type 2 diabetes in obese patients without preexisting diabetes, with incidence rates significantly lower than non-surgical obese controls.
If you are obese but do not yet have diabetes, bariatric surgery can significantly reduce your risk of developing it over the next 15 years compared to lifestyle changes alone. While surgery is invasive, the long-term data shows it is a highly effective preventive strategy for those with severe obesity.
GoodSupportsHIGH confidence
The incidence rates were 28.4 case per 1,000 person-years for the nonoperative group and only 6.8 cases per 1,000 person-years in the gastric bypass group.
Why this rating
Based on the Swedish Obesity Study (SOS), a long-term prospective study, though with limitations in follow-up and procedure types.
Source
Metabolic Surgery Is No Longer Just Bariatric Surgery
Elizabeth C. Moore et al. · Diabetes Technology & Therapeutics · 2014
DOI 10.1089/dia.2014.1509
narrative_reviewCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Roux-en-Y gastric bypass (RYGB) induces remission of type 2 diabetes (T2DM) in patients with BMI 30-35 kg/m2, independent of significant weight loss, by altering gastrointestinal hormone secretion (GLP-1, GIP, GLP-2).Good
- Preoperative factors such as duration of diabetes, high HbA1c, and insulin use predict failure of T2DM remission after bariatric surgery.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →